Currently Viewing:
Evidence-Based Oncology August 2016
Solutions for Reducing Patient Cost Sharing for Medications
Marialanna Lee, MSC; Brian Connell; Elisa Weiss, PhD; and Louis J. DeGennaro, PhD
Charitable Assistance Among Economically Vulnerable Cancer Patients: Patient Access Network Foundation Summary Statistics 2011-2015
Helaine E. Resnick PhD, MPH; Bruce Barth; and Daniel Klein, MHS
The Toll of Cancer Care - Clinical and Financial Toxicity
Joseph Alvarnas, MD
Does the Cost-Sharing Burden Influence Cancer Outcomes?
Surabhi Dangi-Garimella, PhD
Improve Medicare Policy to Remove Barriers to Bone Marrow and Cord Blood Transplants
Jeffrey W. Chell, MD
Proton Therapy Eliminates Unnecessary Radiation Exposure and Is Medically Necessary
Steven J. Frank, MD
Finding Solutions for Cancer Patients: The American Cancer Society's Health Insurance Assistance Service
Katherine Sharpe, MTS; Melissa Fellers; Mandi Battaglia Seiler
Precision Oncology: Why Payers Should Initiate CGP Coverage Now!
Jerry Conway and Ingrid Marino, MS, CGC
Young Adult Cancer Survivors Disproportionately Affected by Treatment Costs
Samantha Watson, MBA, and Michelle Landwehr, MPH
Patient Access to Reference Pricing Prompts Choice of Lower-Cost Testing Laboratories, Cost Savings
Surabhi Dangi-Garimella, PhD
California Experiment Will Let Pathologists Report Cancer Diagnoses in Real Time
Surabhi Dangi-Garimella, PhD
Breakthrough for Daratumumab for Use as Second-Line Treatment With Standard of Care in Multiple Myeloma
Surabhi Dangi-Garimella, PhD
NEJM Study First to Identify Mutations Responsible for Relapse in PD-1 InhibitoróTreated Melanoma
Surabhi Dangi-Garimella, PhD
Nivolumab Passes QOL Test in Melanoma
Surabhi Dangi-Garimella, PhD
Currently Reading
The Risk of T2D in Individuals With Benign Adrenal Tumors
Surabhi Dangi-Garimella, PhD
Health IT Essential for the Success of Cancer Moonshot
Surabhi Dangi-Garimella, PhD
Dissolving Data Silos and Improving Access to Health IT Essential in Oncology Care
Surabhi Dangi-Garimella, PhD

The Risk of T2D in Individuals With Benign Adrenal Tumors

Surabhi Dangi-Garimella, PhD
Adrenal gland tumors that are defined as being nonfunctional may not really be so, and the hormones that these tumors secrete could increase an individualís risk of cardiometabolic irregularities, according to a new study.
Adrenal gland tumors that are defined as being nonfunctional may not really be so, and the hormones that these tumors secrete could increase an individual’s risk of cardiometabolic irregularities, according to a new study published in Annals of Internal Medicine. Tumors in the adrenal glands—abdominal glands that produce hormones and are included in the endocrine system—are classified as benign, functional, and malignant. The benign tumors are typically defined as being noncancerous and are found by chance when diagnostic tests are being conducted to evaluate some other symptoms. However, one of the hormones secreted by these tumors is cortisol, which can increase the risk of cardiovascular and metabolic diseases.

To further study the relation between the development of these tumors and an individual’s risk for cardiometabolic outcomes, researchers conducted a retrospective analysis of medical data gathered from 166 individuals who were documented as having developed the tumors. The control group of 740 individuals did not have adrenal tumors; inclusion criteria was a 3-year follow up period. Patient records were evaluated for an average period of 7.7 years from the time of abdominal imaging following incidental outcomes of hypertension, composite diabetes (prediabetes or type2 diabetes [T2D]), hyperlipidemia, cardiovascular events, or chronic kidney disease.

When the association between exposure status and incident outcomes was analyzed, it was discovered that individuals with the benign tumors had significantly higher risk for incident composite diabetes than those without the tumors. Specifically, 27.3% of those carrying the tumors had an absolute risk of 15.6% (95% CI, 6.9% to 24.3%) and an adjusted risk ratio of 1.87 (CI, 1.17 to 2.98). On the other hand, less than half (11.7%) the participants in the control group developed the risk of composite diabetes. While there was no significant association between nonfunctional adrenal tumors and any of the other cardiovascular outcomes being evaluated, cortisol levels were found associated with the size of the tumors and higher prevalence of T2D.

“Our results indicated that patients with nonfunctional adrenal tumors developed diabetes twice as often as patients without any adrenal tumors. This suggests that even adrenal tumors we deem to have no health risks are in fact associated with an increased risk of developing diabetes,” said Anand Vaidya, MD, MMSc, senior author on the study, in a statement. He recommends that adrenal tumors sould be considered a potential risk factor for the development of diabetes. EBO
REFERENCE
Lopez D, Luque-Fernandez MA, Steele A, Adler GK, Turchin A, Vaidya A. “Nonfunctional” adrenal tumors and the risk for incident diabetes and cardiovascular outcomes: a cohort study [published online August 2, 2016]. Ann Intern Med. doi:10.7326/M16-0547.
PDF
 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!